Bladder Cancer - Pipeline Review, H1 2013


#164486

232pages

Global Markets Direct

$ 2000

In Stock

 

Global Markets Directs, 'Bladder Cancer Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. 

 

Bladder Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Bladder Cancer.
  • A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Bladder Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents


Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Bladder Cancer Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Bladder Cancer 10
Bladder Cancer Therapeutics under Development by Companies 12
Bladder Cancer Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Bladder Cancer Therapeutics - Products under Development by Companies 22
Bladder Cancer Therapeutics - Products under Investigation by Universities/Institutes 26
Companies Involved in Bladder Cancer Therapeutics Development 27
Shionogi & Co., Ltd. 27
Sanofi-Aventis 28
Eli Lilly and Company 29
Viralytics Ltd. 30
GlaxoSmithKline plc 31
Bioniche Life Sciences, Inc. 32
Inovio Biomedical Corporation 33
Bavarian Nordic A/S 34
Biotest AG 35
Eisai Co., Ltd. 36
MDRNA, Inc. 37
Celgene Corporation 38
Advaxis, Inc. 39
Celldex Therapeutics, Inc. 40
AEterna Zentaris Inc. 41
Cleveland BioLabs, Inc. 42
Alnylam Pharmaceuticals, Inc 43
Oncogenex Pharmaceuticals, Inc. 44
Sanochemia Pharmazeutika AG 45
PharmaGap Inc. 46
Quest PharmaTech Inc. 47
Spectrum Pharmaceuticals, Inc. 48
Med Discovery SA 49
Altor BioScience Corporation 50
Telormedix SA 51
Gene Signal International SA. 52
Heat Biologics, Inc. 53
MacroGenics, Inc. 54
Innate Therapeutics Limited 55
Stemline Therapeutics, Inc. 56
BioCancell Therapeutics, Inc. 57
AndroScience Corporation 58
PharmaMar, S.A. 59
Viventia Biotechnologies Inc. 60
TRACON Pharmaceuticals, Inc. 61
Targa Therapeutics Corp. 62
EyeGene, Inc. 63
Serometrix, LLC 64
Regulon Inc. 65
Bladder Cancer - Therapeutics Assessment 66
Assessment by Monotherapy Products 66
Assessment by Combination Products 67
Assessment by Route of Administration 68
Assessment by Molecule Type 70
Drug Profiles 73
AEZS-108 - Drug Profile 73
icrucumab - Drug Profile 75
OGX-427 - Drug Profile 76
MDRG-01 - Drug Profile 78
MDP-01 - Drug Profile 79
paclitaxel - Drug Profile 80
ramucirumab - Drug Profile 82
Urocidin - Drug Profile 86
SL-601 - Drug Profile 88
PVP Hypericin - Drug Profile 89
BT-062 - Drug Profile 90
apaziquone - Drug Profile 92
apaziquone - Drug Profile 94
TMX-101 - Drug Profile 96
TMX-202 - Drug Profile 98
BC-819 - Drug Profile 99
BC-821 - Drug Profile 101
oportuzumab monatox - Drug Profile 102
MDR-09521 - Drug Profile 104
S-288310 - Drug Profile 105
GAP-107B8 - Drug Profile 106
ADXS-HER2 - Drug Profile 108
CVA-21 - Drug Profile 109
SL-052 - Drug Profile 112
MRNA-046 - Drug Profile 114
tauRNAi - Drug Profile 115
PM-00104 - Drug Profile 116
aganirsen - Drug Profile 117
bevacizumab + [gemcitabine hydrochloride] + [cisplatin] - Drug Profile 119
Docetaxel + Gemcitabine - Drug Profile 121
Docetaxel + Gemcitabine + Neupogen - Drug Profile 122
Neuregulin-1 - Drug Profile 124
OGX-427 + [docetaxel] - Drug Profile 125
TRC-105 - Drug Profile 127
larotaxel + [cisplatin] - Drug Profile 129
mTOR/PTEN Bladder Cancer Program - Drug Profile 131
GSK-2132231-A - Drug Profile 132
CDX-1401 + [resiquimod] - Drug Profile 134
rAd-IFN - Drug Profile 135
bevacizumab + [cisplatin] + [doxorubicin] + [methotrexate] + [vinblastine sulfate] - Drug Profile 137
eribulin mesylate + [cisplatin] + [gemcitabine] - Drug Profile 138
margetuximab - Drug Profile 140
cetuximab + [fluorouracil] + [cisplatin] + Radiation Therapy - Drug Profile 142
celecoxib - Drug Profile 144
vandetanib + [carboplatin] + [gemcitabine] - Drug Profile 145
bevacizumab + [cisplatin] + [gemcitabine hydrochloride] + [paclitaxel] - Drug Profile 147
MIS-416 - Drug Profile 148
olaparib + [cisplatin] + [gemcitabine hydrochloride] - Drug Profile 150
ALT-803 - Drug Profile 152
Bacillus Calmette-Guerin Vaccine - Drug Profile 154
HS-410 - Drug Profile 155
MGA-271 - Drug Profile 156
ALT-801 + [cisplatin] + [gemcitabine] - Drug Profile 157
TD-6989 - Drug Profile 159
TD-3633 - Drug Profile 160
TD-1770 - Drug Profile 161
Neo-Bladder Replacement - Drug Profile 162
pazopanib hydrochloride + [vinflunine ditartrate] - Drug Profile 163
VEGF/rGel - Drug Profile 164
OGX-427 + [cisplatin] + [gemcitabine hydrochloride] - Drug Profile 166
BO-110 - Drug Profile 168
CEL-031 - Drug Profile 169
Zycan - Drug Profile 171
Revercom - Drug Profile 172
Mobilan - Drug Profile 173
ASC-JM.Z1 - Drug Profile 174
V-934 - Drug Profile 175
ATX-101 - Drug Profile 177
ATX-101 + Bortezomib - Drug Profile 178
TDO Inhibitor - Drug Profile 179
SX-MTR1 - Drug Profile 180
LNP-dsP21-322-2'F - Drug Profile 181
melphalan flufenamide - Drug Profile 182
DT-310 - Drug Profile 184
DT-320 - Drug Profile 185
DT-330 - Drug Profile 186
Bladder Cancer Therapeutics - Drug Profile Updates 187
Bladder Cancer Therapeutics - Discontinued Products 212
Bladder Cancer Therapeutics - Dormant Products 213
Bladder Cancer - Product Development Milestones 216
Featured News & Press Releases 216
 

Appendix 226
Methodology 226
Coverage 226
Secondary Research 226
Primary Research 226
Expert Panel Validation 226
Contact Us 227
Disclaimer 227


Number of Products Under Development for Bladder Cancer, H1 2013 15
Products under Development for Bladder Cancer - Comparative Analysis, H1 2013 16
Number of Products under Development by Companies, H1 2013 18
Number of Products under Development by Companies, H1 2013 (Contd..1) 19
Number of Products under Development by Companies, H1 2013 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H1 2013 22
Comparative Analysis by Late Stage Development, H1 2013 23
Comparative Analysis by Mid Clinical Stage Development, H1 2013 24
Comparative Analysis by Early Clinical Stage Development, H1 2013 25
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 26
Products under Development by Companies, H1 2013 27
Products under Development by Companies, H1 2013 (Contd..1) 28
Products under Development by Companies, H1 2013 (Contd..2) 29
Products under Development by Companies, H1 2013 (Contd..3) 30
Products under Investigation by Universities/Institutes, H1 2013 31
Shionogi & Co., Ltd., H1 2013 32
Sanofi-Aventis, H1 2013 33
Eli Lilly and Company, H1 2013 34
Viralytics Ltd., H1 2013 35
GlaxoSmithKline plc, H1 2013 36
Bioniche Life Sciences, Inc., H1 2013 37
Inovio Biomedical Corporation, H1 2013 38
Bavarian Nordic A/S, H1 2013 39
Biotest AG, H1 2013 40
Eisai Co., Ltd., H1 2013 41
MDRNA, Inc., H1 2013 42
Celgene Corporation, H1 2013 43
Advaxis, Inc., H1 2013 44
Celldex Therapeutics, Inc., H1 2013 45
AEterna Zentaris Inc., H1 2013 46
Cleveland BioLabs, Inc., H1 2013 47
Alnylam Pharmaceuticals, Inc, H1 2013 48
Oncogenex Pharmaceuticals, Inc., H1 2013 49
Sanochemia Pharmazeutika AG, H1 2013 50
PharmaGap Inc., H1 2013 51
Quest PharmaTech Inc., H1 2013 52
Spectrum Pharmaceuticals, Inc., H1 2013 53
Med Discovery SA, H1 2013 54
Altor BioScience Corporation, H1 2013 55
Telormedix SA, H1 2013 56
Gene Signal International SA., H1 2013 57
Heat Biologics, Inc., H1 2013 58
MacroGenics, Inc., H1 2013 59
Innate Therapeutics Limited, H1 2013 60
Stemline Therapeutics, Inc., H1 2013 61
BioCancell Therapeutics, Inc., H1 2013 62
AndroScience Corporation, H1 2013 63
PharmaMar, S.A., H1 2013 64
Viventia Biotechnologies Inc., H1 2013 65
TRACON Pharmaceuticals, Inc., H1 2013 66
Targa Therapeutics Corp., H1 2013 67
EyeGene, Inc., H1 2013 68
Serometrix, LLC, H1 2013 69
Regulon Inc., H1 2013 70
Assessment by Monotherapy Products, H1 2013 71
Assessment by Combination Products, H1 2013 72
Assessment by Stage and Route of Administration, H1 2013 74
Assessment by Stage and Molecule Type, H1 2013 77
Bladder Cancer Therapeutics - Drug Profile Updates 192
Bladder Cancer Therapeutics - Discontinued Products 217
Bladder Cancer Therapeutics - Dormant Products 218
Bladder Cancer Therapeutics - Dormant Products (Contd..1) 219
Bladder Cancer Therapeutics - Dormant Products (Contd..2) 220


Number of Products under Development for Bladder Cancer, H1 2013 15
Products under Development for Bladder Cancer - Comparative Analysis, H1 2013 16
Products under Development by Companies, H1 2013 17
Products under Investigation by Universities/Institutes, H1 2013 21
Late Stage Products, H1 2013 23
Mid Clinical Stage Products, H1 2013 24
Early Clinical Stage Products, H1 2013 25
Discovery and Pre-Clinical Stage Products, H1 2013 26
Assessment by Monotherapy Products, H1 2013 71
Assessment by Combination Products, H1 2013 72
Assessment by Route of Administration, H1 2013 73
Assessment by Stage and Route of Administration, H1 2013 74
Assessment by Molecule Type, H1 2013 75
Assessment by Stage and Molecule Type, H1 2013 76